Levofloxacin Ameliorates Atherosclerosis By Regulating Lipid Metabolism
Abstract
not-yet-known not-yet-known not-yet-known unknown Atherosclerosis (AS) is a prevalent cardiovascular disease with complex pathogenesis. The pathogenesis of AS encompasses various cellular activities, including endothelial damage, inflammatory responses, oxidative stress, and lipid metabolism, culminating in subintimal lipid deposition in the aorta and its branches. Against the backdrop of existing studies demonstrating that Chlamydia pneumoniae is present in atherosclerotic plaques and that levofloxacin (LEV) can reduce carotid artery cholesterol levels in patients infected with Chlamydia pneumoniae, this study hypothesized that LEV exerts an independent anti-atherosclerotic effect and conducted experimental verification to test this hypothesis. The aim of this study is to provide experimental evidence for the potential application of LEV in the prevention and treatment of AS, while also enriching the theoretical research direction of pharmacological interventions for AS. This study aims to investigate the therapeutic effects of LEV on AS and the potential underlying mechanism mainly by using ApoE-knockout（ApoE -/-）mice fad a high-fat diet. In vivo animal experiments and in vitro cellular experiment on lipid deposition confirm that LEV could effectively reduce blood lipids level, atherosclerotic lesion in aorta, and lipid deposition in cultured macrophages, thereby delaying AS progression. Further research on genes related to hepatic lipid metabolism has revealed that LEV…
How strong is the evidence?
Evidence Hub reads this as a preprint, done in animal and cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.